Mangalam Drugs & Organics Limited
NSE: MANGALAM
NSE
33.42
1.59 (5.00%)
Prev Close
31.83
Open Price
33.42
Volume
467,203
Today Low / High
33.42 / 33.42
52 WK Low / High
22.8 / 124.75
Range
32 - 35
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 33.42, with a change of 1.59 (4.99529%). The expected target range on the NSE is between 32 - 35. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
02 Jan
30.32
0.00%
01 Jan
28.88
0.00%
31 Dec
27.51
0.00%
30 Dec
26.20
0.00%
29 Dec
24.35
2.51%
26 Dec
24.00
-0.92%
24 Dec
24.12
-0.50%
23 Dec
24.59
-2.40%
22 Dec
23.80
1.22%
19 Dec
25.25
-4.91%
18 Dec
25.10
-3.19%
17 Dec
25.17
-0.91%
16 Dec
25.53
-1.88%
15 Dec
25.48
-0.86%
12 Dec
25.40
-0.79%
11 Dec
25.75
-2.64%
10 Dec
25.37
0.20%
Mangalam Drugs & Organics Limited Graph
Mangalam Drugs & Organics Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Mangalam Drugs & Organics Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 33.42, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 33.42 | 33.75 | 30.38 - 37.13 |
| 34.09 | 27.27 - 40.91 | ||
| 34.42 | 24.10 - 44.75 | ||
| Bearish Scenario | 33.42 | 33.09 | 29.78 - 36.39 |
| 32.75 | 26.20 - 39.30 | ||
| 32.42 | 22.69 - 42.14 |
Overview of Mangalam Drugs & Organics Limited
ISIN
INE584F01014
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
141,445
Market Cap
479,912,479
Last Dividend
0
Official Website
IPO Date
2005-05-23
DCF Diff
53.42
DCF
-23
Financial Ratios Every Investor Needs
Stock Dividend of MANGALAM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2017-12-21 | December 21, 17 | 0.5 | 0.5 | 2017-12-22 | 2017-12-29 | 2017-12-12 |
| 2011-09-20 | September 20, 11 | 2 | 2 | |||
| 2006-09-19 | September 19, 06 | 0.2 | 0.2 | |||
| 2005-08-30 | August 30, 05 | 0.2 | 0.2 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 317.58 Cr | 167.37 Cr | 150.21 Cr | 0.4730 | 3.47 Cr | 40.59 Cr | 17.40 Cr | 6.72 Cr | 4.25 | 36.33 Cr | 0.0212 |
| 2024-03-31 | 367.35 Cr | 348.54 Cr | 18.81 Cr | 0.0512 | 3.27 Cr | 9.51 Cr | 1.06 Cr | -9.07 Cr | -5.73 | 17.49 Cr | -0.0247 |
| 2023-03-31 | 370.20 Cr | 341.42 Cr | 28.78 Cr | 0.0777 | 3.32 Cr | 9.25 Cr | 15.10 Cr | 1.27 Cr | 0.80 | 25.95 Cr | 0.0034 |
| 2022-03-31 | 447.37 Cr | 392.68 Cr | 54.69 Cr | 0.1222 | 2.96 Cr | 7.77 Cr | 35.57 Cr | 19.66 Cr | 12.42 | 45.18 Cr | 0.0439 |
| 2021-03-31 | 379.80 Cr | 282.13 Cr | 97.67 Cr | 0.2572 | 2.25 Cr | 6.24 Cr | 44.45 Cr | 27.97 Cr | 17.67 | 55.02 Cr | 0.0736 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2.59 Cr | 366.42 Cr | 217.44 Cr | 148.9790 Cr | 96.23 Cr | 93.64 Cr | 138.80 Cr | 133.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 191.5994 Cr |
| 2024-03-31 | 1.19 Cr | 333.70 Cr | 197.91 Cr | 135.7930 Cr | 106.99 Cr | 105.81 Cr | 123.64 Cr | 129.08 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 164.0611 Cr |
| 2023-03-31 | 2.68 Cr | 359.63 Cr | 207.67 Cr | 151.9562 Cr | 88.55 Cr | 85.87 Cr | 137.47 Cr | 134.43 Cr | 0.26 Cr | 0.00 Cr | 0.00 Cr | 165.3575 Cr |
| 2022-03-31 | 1.95 Cr | 328.43 Cr | 177.86 Cr | 150.5614 Cr | 87.90 Cr | 85.96 Cr | 117.11 Cr | 129.21 Cr | 10.49 Cr | 0.00 Cr | 0.00 Cr | 130.1133 Cr |
| 2021-03-31 | 0.58 Cr | 264.11 Cr | 133.32 Cr | 130.7860 Cr | 69.71 Cr | 69.12 Cr | 58.59 Cr | 117.54 Cr | 0.00 Cr | 0.00 Cr | 0.22 Cr | 109.0776 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 42.5941 Cr | -19.4724 Cr | -21.7124 Cr | 22.3929 Cr | 1.4093 Cr | 2.5889 Cr | -20.2012 Cr | 6.7207 Cr | -6.7094 Cr | 0.0000 Cr | -15.1621 Cr |
| 2024-03-31 | 3.9126 Cr | -11.8274 Cr | 5.2267 Cr | -7.9201 Cr | -1.5011 Cr | 1.1796 Cr | -11.8327 Cr | -9.0717 Cr | 12.4869 Cr | 0.0000 Cr | 16.8876 Cr |
| 2023-03-31 | 39.5231 Cr | -22.1723 Cr | -16.6171 Cr | 11.6094 Cr | 0.7338 Cr | 2.6807 Cr | -27.9137 Cr | 2.2138 Cr | -3.8658 Cr | 0.0000 Cr | -20.3609 Cr |
| 2022-03-31 | 25.7091 Cr | -27.3257 Cr | 2.9793 Cr | -1.9599 Cr | 1.3627 Cr | 1.9469 Cr | -27.6690 Cr | 27.7330 Cr | 14.1411 Cr | 0.0000 Cr | -58.5180 Cr |
| 2021-03-31 | 27.5497 Cr | -31.2853 Cr | 2.6983 Cr | -3.8864 Cr | -1.0373 Cr | 0.5918 Cr | -31.4361 Cr | 39.5191 Cr | 13.4421 Cr | 0.0000 Cr | 6.2551 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 49.26 Cr | 33.06 Cr | 16.20 Cr | 0.3289 | -7.47 Cr | -7.35 Cr | -4.64 | -2.81 Cr | -0.1491 |
| 2025-06-30 | 57.21 Cr | 45.73 Cr | 11.48 Cr | 0.2007 | -8.95 Cr | -13.80 Cr | -8.72 | -4.48 Cr | -0.2412 |
| 2025-03-31 | 72.78 Cr | 35.36 Cr | 37.41 Cr | 0.5141 | 5.45 Cr | 0.06 Cr | 0.04 | 9.61 Cr | 0.0008 |
| 2024-12-31 | 88.55 Cr | 50.93 Cr | 37.62 Cr | 0.4249 | 4.72 Cr | 1.29 Cr | 0.81 | 8.91 Cr | 0.0145 |
| 2024-09-30 | 79.75 Cr | 40.66 Cr | 39.09 Cr | 0.4901 | 4.73 Cr | 2.69 Cr | 1.70 | 8.84 Cr | 0.0337 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 3.38 Cr | 6.30 Cr | 9.67 Cr | 18.10 Cr | 116.94 Cr | 152.78 Cr | 132.18 Cr | 316.72 Cr | 189.15 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 2.59 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -148.98 Cr |
| 2025-03-31 | 2.59 Cr | 0.00 Cr | 2.59 Cr | 40.17 Cr | 138.80 Cr | 198.98 Cr | 133.60 Cr | 366.42 Cr | 217.44 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 6.09 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -147.97 Cr |
| 2024-09-30 | 6.09 Cr | 0.00 Cr | 6.09 Cr | 26.74 Cr | 142.95 Cr | 200.97 Cr | 130.79 Cr | 364.11 Cr | 216.14 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -13.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 0.06 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 1.29 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 2.69 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 2.68 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,761.70 | ₹4,226,908,416,649.00 | ₹1,472,684.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,649.00 | ₹1,765,100,588,420.00 | ₹672,729.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,933.50 | ₹1,331,275,138,240.00 | ₹159,854.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,256.30 | ₹1,045,885,485,158.00 | ₹474,864.00 |
| Lupin Limited | LUPIN | ₹2,152.80 | ₹983,396,469,557.00 | ₹1,450,118.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹929.75 | ₹935,546,052,203.00 | ₹340,641.00 |
| Mankind Pharma Limited | MANKIND | ₹2,240.30 | ₹924,807,202,802.00 | ₹236,960.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,233.00 | ₹716,128,401,159.00 | ₹1,687,647.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,658.00 | ₹676,498,770,000.00 | ₹74,886.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,115.90 | ₹602,425,959,854.00 | ₹1,054,080.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,074.60 | ₹585,453,798,351.00 | ₹186,001.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,470.00 | ₹372,945,200,460.00 | ₹585,877.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,846.80 | ₹355,666,734,403.00 | ₹279,657.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,879.00 | ₹294,347,146,324.00 | ₹211,140.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,530.10 | ₹290,064,943,454.00 | ₹281,696.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,467.00 | ₹238,376,011,923.00 | ₹901,810.00 |
| Eris Lifesciences Limited | ERIS | ₹1,552.50 | ₹211,476,723,278.00 | ₹31,549.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,407.00 | ₹210,175,000,000.00 | ₹37,561.00 |
| Cohance Lifesciences Limited | COHANCE | ₹503.45 | ₹192,603,426,633.00 | ₹402,100.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹14,520.00 | ₹186,289,988,280.00 | ₹66,617.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,080.40 | ₹171,241,709,174.00 | ₹154,663.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹925.75 | ₹165,810,962,153.00 | ₹1,143,584.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹826.80 | ₹162,518,390,923.00 | ₹53,139.00 |
| Granules India Limited | GRANULES | ₹613.00 | ₹148,755,922,908.00 | ₹481,822.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,842.80 | ₹140,074,353,389.00 | ₹31,582.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹907.60 | ₹111,345,591,445.00 | ₹34,897.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,795.50 | ₹96,201,718,381.00 | ₹4,150.00 |
| Strides Pharma Science Limited | STAR | ₹987.35 | ₹91,006,729,168.00 | ₹1,033,249.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹443.95 | ₹67,969,658,649.00 | ₹54,474.00 |
| FDC Limited | FDC | ₹412.55 | ₹67,167,300,154.00 | ₹92,294.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹736.30 | ₹66,743,602,572.00 | ₹83,116.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹318.25 | ₹62,243,912,942.00 | ₹104,610.00 |
| Sequent Scientific Limited | SEQUENT | ₹206.80 | ₹51,663,565,769.00 | ₹340,926.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹420.50 | ₹45,819,893,933.00 | ₹29,638.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹136.29 | ₹44,229,047,229.00 | ₹844,523.00 |
| Innova Captab Limited | INNOVACAP | ₹728.50 | ₹41,688,360,777.00 | ₹9,669.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹782.70 | ₹39,697,843,484.00 | ₹40,095.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,332.90 | ₹38,583,868,094.00 | ₹2,487.00 |
| Suven Life Sciences Limited | SUVEN | ₹170.52 | ₹37,583,633,678.00 | ₹748,782.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹403.50 | ₹36,827,445,000.00 | ₹87,942.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹329.40 | ₹33,033,057,476.00 | ₹13,223.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹434.45 | ₹30,587,778,088.00 | ₹4,669.00 |
Key Executives
General Manager
Bhanvesh Dinesh Naik
Gender: Not Specified
Year Born: 1979
General Manager
Rakesh Sakikram Srivastava
Gender: male
Year Born: 1974
President
Kamal Ishvarlal Vashi
Gender: Not Specified
Year Born: 1980
Whole-Time Director
Brijmohan Murlidhar Dhoot
Gender: male
Year Born: 1951
Chairman & MD
Govardhan Murlidhar Dhoot
Gender: male
Year Born: 1953
Head of Purchase
Yaduraj Dhoot
Gender: male
Year Born: 2000
Company Secretary & Compliance Officer
Anuradha Pandey
Gender: female
Year Born: 1993
Chief Operating Officer
Krishnapriya Nawal
Gender: female
Year Born: 1985
Senior Manager
Mansi Sidhinath Pathak
Gender: female
Year Born: 1979
FAQs about Mangalam Drugs & Organics Limited
Who is the CEO of the company?
The CEO is Govardhan Murlidhar Dhoot.
What is the current market price of the stock?
The current price is ₹30.32.
What is the 52-week price range?
The range is ₹22.8-124.75.
What is the market capitalization of the company?
The market capitalization is ₹47.99 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -2.42.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Mangalam Drugs & Organics Limited (ISIN: INE584F01014) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹47.99 crores and an average daily volume of 141,445 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.